Table 3.

Base‐case results

	Dapagliflozin + standard therapy	Standard therapy	Incremental
UK
Total costs	£16 408	£13 628	£2780
Treatment, monitoring and adverse events	£4287	£1917	£2370
Worsening HF events and CV death	£3851	£4229	– £378
Background resource use	£8270	£7482	£788
Total LYs	6.20	5.62	0.58
Total QALYs	4.61	4.13	0.48
ICER	–	–	£5822/QALY
Germany
Total costs	€25 328	€22 647	€2681
Treatment, monitoring and adverse events	€7637	€5059	€2578
Worsening HF events and CV death	€9944	€10 598	– €655
Background resource use	€7747	€6990	€757
Total LYs	6.35	5.74	0.61
Total QALYs	4.72	4.22	0.50
ICER	–	–	€5379/QALY
Spain
Total costs	€24 330	€19 642	€4688
Treatment, monitoring and adverse events	€10 139	€5785	€4354
Worsening HF events and CV death	€5425	€5945	– €520
Background resource use	€8766	€7912	€854
Total LYs	6.35	5.74	0.61
Total QALYs	4.72	4.22	0.50
ICER	–	–	€9406/QALY
Clinical events a
HHF (per 1000 treated patients)	820	925	−105
Urgent HF visit (per 1000 treated patients)	32	54	−22
1‐year survival	91.8%	90.3%	1.6%
2‐year survival	82.7%	79.6%	3.1%
5‐year survival	56.6%	50.9%	5.7%

CV, cardiovascular; HF, heart failure; HHF, hospitalization for heart failure; ICER, incremental cost‐effectiveness ratio; LY, life‐year; QALY, quality‐adjusted life‐years.

^aClinical events reported relate to output from the UK model.